Steven Feldman to Calcitriol
This is a "connection" page, showing publications Steven Feldman has written about Calcitriol.
Connection Strength
4.933
-
Feldman SR, Levi E, Pathak P, Kakatkar S, Balkrishnan R. First-Line Fixed-Combination Psoriasis Treatment Is Associated With Lower Healthcare Costs. Skinmed. 2016; 14(4):266-272.
Score: 0.547
-
Kin KC, Hill D, Feldman SR. Calcipotriene and betamethasone dipropionate for the topical treatment of plaque psoriasis. Expert Rev Clin Pharmacol. 2016 Jun; 9(6):789-97.
Score: 0.538
-
Sandoval LF, Huang KE, Harrison J, Clark A, Feldman SR. Calcipotriene 0.005%--betamethasone dipropionate 0.064% ointment versus topical suspension in the treatment of plaque psoriasis: a randomized pilot study of patient preference. Cutis. 2014 Dec; 94(6):304-9.
Score: 0.487
-
Feldman SR, Levi E, Pathak P, Kakatkar S, Balkrishnan R. Using a single product (calcipotriene/betamethasone topical suspension) vs multiple products to manage body and scalp psoriasis: comparisons in resource utilization and costs. J Med Econ. 2013 Dec; 16(12):1405-13.
Score: 0.451
-
Davis SA, Feldman SR. Combination therapy for psoriasis in the United States. J Drugs Dermatol. 2013 May; 12(5):546-50.
Score: 0.436
-
Feldman SR, Mills M, Brundage T, Eastman WJ. A multicenter, randomized, double-blind study of the efficacy and safety of calcipotriene foam, 0.005%, vs vehicle foam in the treatment of plaque-type psoriasis of the scalp. J Drugs Dermatol. 2013 Mar; 12(3):300-6.
Score: 0.431
-
Feldman SR, Matheson R, Bruce S, Grande K, Markowitz O, Kempers S, Brundage T, Wyres M. Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis: results of two multicenter, randomized, double-blind, vehicle-controlled, phase III clinical trials. Am J Clin Dermatol. 2012 Aug 01; 13(4):261-71.
Score: 0.414
-
Sigmon JR, Yentzer BA, Feldman SR. Calcitriol ointment: a review of a topical vitamin D analog for psoriasis. J Dermatolog Treat. 2009; 20(4):208-12.
Score: 0.323
-
Feldman SR. Many new options for improving patients' care. J Dermatolog Treat. 2009; 20(4):185.
Score: 0.323
-
Pearce DJ, Camacho F, Balkrishnan R, Fleischer AB, Feldman SR. Trends in on and off-label calcipotriene use. J Dermatolog Treat. 2006; 17(5):308-13.
Score: 0.262
-
Lebwohl M, Menter A, Koo J, Feldman SR. Combination therapy to treat moderate to severe psoriasis. J Am Acad Dermatol. 2004 Mar; 50(3):416-30.
Score: 0.231
-
Asche CV, Kim M, Feldman SR, Zografos P, Lu M. Budget impact model in moderate-to-severe psoriasis vulgaris assessing effects of calcipotriene and betamethasone dipropionate foam on per-patient standard of care costs. J Med Econ. 2017 Sep; 20(9):1000-1006.
Score: 0.145
-
Ahn CS, Awadalla F, Huang KE, Yentzer B, Dabade TS, Feldman SR. Patterns of vitamin D analog use for the treatment of psoriasis. J Drugs Dermatol. 2013 Aug; 12(8):906-10.
Score: 0.111
-
Strowd LC, Yentzer BA, Fleischer AB, Feldman SR. Increasing use of more potent treatments for psoriasis. J Am Acad Dermatol. 2009 Mar; 60(3):478-81.
Score: 0.080
-
Pearce DJ, Stealey KH, Balkrishnan R, Fleischer AB, Feldman SR. Psoriasis treatment in the United States at the end of the 20th century. Int J Dermatol. 2006 Apr; 45(4):370-4.
Score: 0.067
-
Gao JC, Emmerich VK, Feldman S, Strowd LC. Evaluating calcipotriene 0.005% foam for the treatment of plaque psoriasis of the scalp and body in patients aged 12 years and older. Expert Opin Pharmacother. 2021 Apr; 22(5):543-547.
Score: 0.046
-
Wong JW, Davis SA, Feldman SR, Koo JY. Trends in older adult psoriasis outpatient health care practices in the United States. J Drugs Dermatol. 2012 Aug; 11(8):957-62.
Score: 0.026
-
Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB. A systematic review of adverse effects associated with topical treatments for psoriasis. Dermatol Online J. 2003 Feb; 9(1):2.
Score: 0.013